P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTSRaija Silvennoinen,Anu Partanen,Anders Waage,Valdas Pečeliūnas, Fredrik Schjesvold,Pekka Anttila,Katarina Uttervall,Marjaana Säily,Matti Putkonen,Kristina Carlson,Einar Haukås, Marja Sankelo,Damian Szatkowski,Markus Hansson,Anu Marttila, Per Axelsson,Ronald Svensson,Birgitta Lauri,Maija Mikkola,Conny Karlsson,Johanna Abelsson,Erik Ahlstrand,Anu Sikiö,Monika Klimkowska,Rėda Matuzevičienė, Mona Hoyseter Fenstad,Sorella Ilveskero,Hareth NahiHemaSphere（2023）引用 0|浏览13暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
